A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Conditions: Osteosarcoma; Sarcoma; Sarcoma,Soft Tissue; Bone Tumor Intervention: Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130) Sponsors: Shanghai Yunying Medical Technology; Xi'an Honghui Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Cold Sores | Herpes | Hospitals | Osteosarcoma | Research | Sarcomas | Study